Botson, John K.
Obermeyer, Katie
LaMoreaux, Brian
Zhao, Lin
Weinblatt, Michael E.
Peterson, Jeff
Funding for this research was provided by:
Horizon Therapeutics plc
Article History
Received: 2 August 2022
Accepted: 13 December 2022
First Online: 27 December 2022
Declarations
:
: This multi-center, open-label, single-arm efficacy and safety study (NCT03635957) was approved by the Western IRB (Puyallup, WA). Patients provided written informed consent and all study conduct adhered to the tenets of the Declaration of Helsinki.
: Not applicable.
: JKB: Received research support from Horizon and Radius Health as a study site and principal investigator, received consulting/speaker fees from Abbvie, Amgen, Aurinia, Chemocentryx, Horizon Therapeutics, Lilly, and Novartis. KO, BL, LZ: Employees of and stockholders in Horizon. MEW: Received grants from Amgen, Bristol-Myers Squibb, Lilly, and Sanofi. Received consulting fees greater than $10,000 USD from Chemocentryx, CorEvitas, and Genosco and less than $10,000 USD from AbbVie, Amgen, Aclaris, Arena, Bayer, Bristol Meyer Squibb, Crescendo, Myriad Genetics, EqRx, GlaxoSmithKline, Gilead Sciences, Horizon Therapeutics, Johnson and Johnson, Kaleido, Kinisksa, Kyverna, Eli Lilly, Novartis, Pfizer, Rani Therapeutics, RPharma, Roche, Scipher Medicine, Set Point, Tremeau, and XBiortech; he has stock options in Can-Fite BioPharma, Scipher Medicine, Inmedix, and Vorso and royalties from Elsevier as co-editor for the textbook <i>Rheumatology</i>. JP: Research support from Horizon Therapeutics as a study site and investigator and has received consulting/speaker fees from Horizon Therapeutics, Lilly, and Novartis.